Pfizer Corporation

Wyeth

Amarnauth Shastrie Prashad

Leo J Letendre

Xiaotian Zhong

Robert Wayne Dugger

Tao He

Wenge Wang

Ronald William Kriz

Will Somers

Vimalkumar Babubhai Patel

Chunchun Zhang

Allan Wissner

Derek Cecil Cole

Diane H Boschelli

Russell Dushin

Lawrence Nathan Tumey

Magda Asselin

Biqi Wu

Yanong Daniel Wang

Diane Marie Joseph-McCarthy

Matthew Olson

Jose Manuel Gomes

Chuan S Niu

Martin Di Grandi

Joan Chen

Kaushik Dutta

Frank W Kotch

Vimalkumar B Patel

Renee L Procopio-melino

Diane Harris Boschelli

Diane Marie Joseph-Mccarthy

Leo Joseph Letendre

Diane Marie Joseph-Mcarthy

Renee L Procopio-Melino

Optimizing production of selectively capped, and uncapped, cysteines on antibodies by manipulation of cell growth conditions including the deliberate depletion of cysteine and/or cystine in the cell culture process by way of media components, batch duration, or cell density to achieve efficient production of proteins including antibody-drug-conjugates (ADCs).; conjugating a TNB-capped cysteine-containing protein by reacting it with a reducing agent capable of detaching the TNB-capping moieties from the protein without significantly reducing antibody inter-chain sulfur bonds, and conjugating reduced sulfur bonds on the protein to a payload through a reactive linking moiety.

Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation

An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.

Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation

The present invention relates to intermediates of Formula I and to methods of synthesizing and purifying calicheamicin derivatives.

Intermediates and methods for synthesizing calicheamicin derivatives

The present teachings provide compounds of formula I and their pharmaceutically acceptable salts, hydrates, and esters, wherein R, R, and X are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of formula I to a mammal including a human.

Substituted 3-cyanopyridines as protein kinase inhibitors

The present invention is directed to compound of formula (A): 

1,2-Dihydroquinoline derivatives and method for using the same to treat HIV infections

Growing community of inventors

New City, NY, United States of America

Amarnauth Shastrie Prashad